No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VTYX240816C3000
- 0.25
- +0.10+66.67%
15min DelayClose Jul 22 15:53 ET
0.25High0.10Low
0.10Open0.15Pre Close472 Volume465 Open Interest3.00Strike Price7.55KTurnover103.73%IV16.07%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.4571Delta0.5250Gamma12.44Leverage Ratio-0.0063Theta0.0007Rho5.69Eff Leverage0.0029Vega
Intraday
- 5D
- Daily
News
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
ONGOING INVESTIGATION: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
ONGOING INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
Comments
$Ventyx Biosciences(VTYX.US$
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semag...
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semag...
1
1
$Ventyx Biosciences(VTYX.US$ Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant Nlrp3 Inhibitor Vtx3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
1
$Ventyx Biosciences(VTYX.US$ $NIO Inc(NIO.US$ $Eli Lilly and Co(LLY.US$ $Structure Therapeutics(GPCR.US$
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Morning Movers
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
25
3
Read more
72839823 : Why is stock going down?